Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 NOV 17 ... developed grade II-IV acute graft-versus-host disease (GVHD) and 8 developed extensive chronic GVHD. With median follow-up of 39.1 months, event free survival and overall survival ... GVHD in 4 (1 acute GVHD and 3 chronic GVHD), veno-occlusive disease in 1 and fulminant hepatitis in 1. transplanted CB had event free survival of 57.1%, comparable to 63.2% for those ...
2009 NOV 28 ... highly amenable to combination with other anti-virals for the treatment of patients with chronic hepatitis C infection. About Inhibitex Inhibitex, Inc., headquartered in Alpharetta, Georgia, is a ...
2009 NOV 23 ... training and expertise to expand our offerings into disease management services for chronic conditions like diabetes, hypertension and hyperlipidemia." MinuteClinic ... joint sprains are treated, and common vaccinations such as influenza, tetanus, MMR, and Hepatitis A & B are available at all locations. In addition, MinuteClinic administers a series of ...
2009 NOV 23 ... research, and medical management referral program for chronic hepatitis B and chronic hepatitis C virus infection afflicting millions of Americans, the National Viral Hepatitis ...
2009 NOV 23 ... their study in Annals of Clinical Biochemistry (Hypobetalipoproteinaemia secondary to chronic hepatitis C virus infection in a patient with familial hypercholesterolaemia. Annals of Clinical ...
2009 NOV 23 ... entecavir in nucleoside-naive patients with hepatitis B virus e antigen (HBeAg)-positive chronichepatitis B was established in a large, international, double-dummy study (ETV-022) ...
2009 NOV 23 ... to PEG-IFN-alpha/RBV combination therapy in 293 Australian individuals with genotype 1 chronic hepatitis C, with validation in an independent replication cohort consisting of 555 individuals. We ...
2009 NOV 23 ... "Hepatitis B and C viruses (HBV and HCV) cause chronichepatitis and hepatocellular carcinoma (HCC) by poorly understood mechanisms. We show ...
2009 NOV 23 ... animal model for hepatitis C' have been presented. "Hepatitis C virus (HCV) causes chronic liver disease and affects an estimated 3% of the world's population. Options for the ...
2009 NOV 23 ... in the journal Transplantation report. "Among 575 patients listed for chronic liver disease, 218 (37.9%) underwent LT and 115 (20%) were removed from the list (76 ... and 69%, P<0.001). These two variables had no impact on survival after LT, except in hepatitis C virus positive recipients. The multivariate Cox model confirmed a positive transplant ...
2009 NOV 23 ... According to recent research from the United States, "Chronic expression of CXC chemokine ligand 10 (CXCL10) in the central nervous system (CNS) ... nervous system (CNS) following infection with the neurotropic JHM strain of mouse hepatitis virus (JHMV) is associated with an immune-mediated demyelinating disease. Treatment of ...
2009 NOV 23 ... According to a study from Nagoya, Japan, "The recommended treatment for patients with chronic hepatitis C, pegylated interferon-alpha (PEG-IFN-alpha) plus ribavirin (RBV), does not provide ...
2009 NOV 23 ... 'Hepatitis B and C virus-related carcinogenesis' new findings in hepatitis B virus. "Chronichepatitis B virus (HBV) and hepatitis C virus (HCV) infection are the most important ...
2009 NOV 23 ... (CTP) score in predicting the prognosis after othotopic liver transplantation (OLT) for chronic severe hepatitis B (CSHB) and explore the prognostic factors. The outcome of 137 ...
2009 NOV 24 ... Himes was responsible for all clinical programs at Coley, including oncology, chronic hepatitis C and autoimmunity, with direct oversight of clinical operations, outsourcing, data ...
2009 NOV 16 ... for taribavirin, a prodrug of ribavirin which is in development for the treatment of chronic hepatitis C in conjunction with a pegylated interferon, were presented at the American Association ...
